Table 1. Antibiotic susceptibility profiles of ST131 Escherichia coli strains, Italy, December 2022–July 2023 (n = 10).
| Strain | Isolation date | Specimen | Ward | AMC S≤0,25 R>0,5 |
P/T S≤8 R>8 |
FEP S≤1 R>4 |
CTX S≤2 R>2 |
CAZ S≤1 R>4 |
CZA S≤8 R>8 |
C/T S≤2 R>2 |
CFX S≤8 R>8 |
CRX S≤1 R>2 |
CIP S≤0.25 >0.5 |
LVX S≤0.5 R>1 |
ERT S≤0.5 R>0.5 |
IMP S≤2 R>4 |
MEM S≤2 R>8 |
AK S≤8 R>8 |
CN S≤2 R>2 |
SXT S≤2 R>4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32829 | Dec 2022 | Blood | Intensive care unit | >32/2 (R) | >32/4 (R) | >16 (R) | >4 (R) | >16 (R) | 0,5/4 (S) | >2/4 (R) | >16 (R) | >4 (R) | >1 (R) | 2 (R) | 1 (R) | 2 (S) | 0,25 (S) | ≤4 (S) | ≤1 (S) | >8/152 (R) |
| 7662 | Dec 2022 | Rectal swab | Infectious diseases | >32/2 (R) | >32/4 (R) | >16 (R) | >4 (R) | >16 (R) | 2/4 (S) | >2/4 (R) | >16 (R) | >4 (R) | >1 (R) | >8 (R) | >2 (R) | 4 (I) | 2 (S) | ≤4 (S) | ≤1 (S) | ≤1/19 (S) |
| 7730 | Jan 2023 | Urine | Infectious diseases | >32/2 (R) | >16/4 (R) | >8 (R) | >4 (R) | >8 (R) | 0,125 (S) | 32/4 (R) | >8 (R) | >4 (R) | >1 (R) | >2 (R) | >1 (R) | 4 (I) | 4 (I) | 16 (R) | >4 (R) | ≤1/19 (S) |
| 7944 | Feb 2023 | Nasopharyngeal aspirate | Pneumology | >32/2 (R) | >16/4 (R) | 8 (R) | >4 (R) | 8 (R) | 0,064 (S) | 4/4 (R) | >8 (R) | >4 (R) | >1 (R) | >2 (R) | >1 (R) | 0,5 (S) | 0,25 (S) | 8 (S) | >4 (R) | ≤1/19 (S) |
| 8136 | Mar 2023 | Rectal swab | Intensive care unit | >32/2 (R) | >32/4 (R) | >16 (R) | >4 (R) | >16 (R) | 0,5/4 (S) | >2/4 (R) | >16 (R) | >4 (R) | >1 (R) | >8 (R) | >2 (R) | ≤0,25 (S) | 2 (S) | ≤4 (S) | ≤1 (S) | >8/152 (R) |
| 8171 | Apr 2023 | Rectal swab | General medicine | >32/2 (R) | >32/4 (R) | >16 (R) | >4 (R) | >16 (R) | 1/4 (S) | >2/4 (R) | >16 (R) | >4 (R) | >1 (R) | >8 (R) | >2 (R) | 1 (S) | 2 (S) | ≤4 (S) | 2 (S) | ≤1/19 (S) |
| 8270 | May 2023 | Urine | Intensive care unit | >32/2 (R) | >32/4 (R) | >16 (R) | >4 (R) | >16 (R) | 4/4 (S) | >2/4 (R) | >16 (R) | >4 (R) | >1 (R) | >8 (R) | >2 (R) | 1 (S) | 2 (S) | ≤4 (S) | ≤1 (S) | ≤1/19 (S) |
| 8345 | May 2023 | Rectal swab | Surgery | >32/2 (R) | >32/4 (R) | 8 (R) | >4 (R) | >16 (R) | 0,5/4 (S) | >2/4 (R) | >16 (R) | >4 (R) | >1 (R) | >8 (R) | >2 (R) | 8 (R) | 2 (S) | ≤4 (S) | ≤1 (S) | ≤1/19 (S) |
| 8638 | Jul 2023 | Nasopharyngeal aspirate | Pneumology | >32/2 (R) | >64/4 (R) | 8 (R) | >4 (R) | 8 (R) | 0,5/4 (S) | >4/4 (R) | >8 (R) | >4 (R) | >1 (R) | >1 (R) | 1 (R) | ≤0,25 (S) | 0,25 (S) | 8 (S) | >4 (R) | ≤1/19 (S) |
| 8718 | Jul 2023 | Rectal swab | Surgery | >32/2 (R) | 64/4 (R) | >8 (R) | >4 (R) | >16 (R) | 0,5/4 (S) | 2/4 (S) | >8 (R) | >4 (R) | >1 (R) | >1 (R) | >1 (R) | ≤0,25 (S) | ≤0,125 (S) | 8 (S) | 2 (S) | ≤1/19 (S) |
AK: amikacin; AMC: amoxicillin/clavulanate; CAZ: ceftazidime; CFX: cefuroxime; CFZ: cefazolin; CIP: ciprofloxacin; CN: gentamycin; CRX: ceftriaxone; C/T: ceftolozane/tazobactam; CTX: cefotaxime; CZA: ceftazidime/avibactam; ETP: ertapenem; FEP: cefepime; IMP: imipenem; LVX: levofloxacin; MEM: meropenem; P/T: piperacillin/tazobactam; SXT: trimethoprim/sulfamethoxazole.
Interpretation according to EUCAST breakpoints [7] are displayed in brackets.